Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry

杜皮鲁玛 医学 特应性皮炎 皮肤科生活质量指数 湿疹面积及严重程度指数 皮肤病科 不利影响 生活质量(医疗保健) 观察研究 相伴的 加药 疾病严重程度 内科学 银屑病 护理部
作者
Angela L. Bosma,Linde E. M. de Wijs,Michel H. Hof,Beau R. van Nieuwenhuizen,Louise A. A. Gerbens,Maritza A. Middelkamp‐Hup,DirkJan Hijnen,Phyllis I. Spuls
出处
期刊:Journal of The American Academy of Dermatology [Elsevier BV]
卷期号:83 (5): 1375-1384 被引量:50
标识
DOI:10.1016/j.jaad.2020.05.128
摘要

BackgroundEvidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking.ObjectiveTo investigate patient characteristics, treatment aspects, effectiveness, and safety of up to 84 weeks of dupilumab treatment.MethodsAn observational prospective cohort study was conducted of patients with atopic dermatitis starting dupilumab in routine clinical care.ResultsOf the 221 included patients, 103 used systemic therapy at baseline. At 84 weeks, we found a change of −15.2 (SE, 1.7) for the Eczema Area and Severity Index, −16.9 (SE, 1.4) for the Patient-Oriented Eczema Measure, and −17.2 (SE, 1.6) for the Dermatology Life Quality Index. We found a trend for improvement over time for the Investigator Global Assessment and Numerical Rating Scale for pruritus. Severe (n = 79) including serious (n = 11) adverse events were observed in 69 patients. Eye complaints were most frequently reported (n = 46). Twenty-one patients adjusted the regular dosing schedule, and 14 patients discontinued treatment, mainly due to ineffectiveness (n = 7).LimitationsOnly adverse events of severe and serious nature were registered for feasibility reasons.ConclusionDaily practice dupilumab treatment of up to 84 weeks is generally well-tolerated, apart from the reporting of eye complaints. It can be considered a long-term effective treatment for atopic dermatitis in combination with topical and initial concomitant systemic treatment, showing a sustained improvement of signs, symptoms, and quality of life. Evidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking. To investigate patient characteristics, treatment aspects, effectiveness, and safety of up to 84 weeks of dupilumab treatment. An observational prospective cohort study was conducted of patients with atopic dermatitis starting dupilumab in routine clinical care. Of the 221 included patients, 103 used systemic therapy at baseline. At 84 weeks, we found a change of −15.2 (SE, 1.7) for the Eczema Area and Severity Index, −16.9 (SE, 1.4) for the Patient-Oriented Eczema Measure, and −17.2 (SE, 1.6) for the Dermatology Life Quality Index. We found a trend for improvement over time for the Investigator Global Assessment and Numerical Rating Scale for pruritus. Severe (n = 79) including serious (n = 11) adverse events were observed in 69 patients. Eye complaints were most frequently reported (n = 46). Twenty-one patients adjusted the regular dosing schedule, and 14 patients discontinued treatment, mainly due to ineffectiveness (n = 7). Only adverse events of severe and serious nature were registered for feasibility reasons. Daily practice dupilumab treatment of up to 84 weeks is generally well-tolerated, apart from the reporting of eye complaints. It can be considered a long-term effective treatment for atopic dermatitis in combination with topical and initial concomitant systemic treatment, showing a sustained improvement of signs, symptoms, and quality of life.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
2秒前
2秒前
万能图书馆的应助被小明同学采纳,获得10
2秒前
3秒前
3秒前
曾国强完成签到,获得积分10
4秒前
4秒前
拖鞋发布了新的文献求助10
4秒前
补兑补完成签到,获得积分10
5秒前
5秒前
6秒前
7秒前
MRCHONG发布了新的文献求助10
7秒前
搜集达人的应助被暮离采纳,获得10
8秒前
8秒前
已知发布了新的文献求助10
8秒前
时嗷完成签到,获得积分10
9秒前
苹果南烟发布了新的文献求助10
9秒前
9秒前
quan发布了新的文献求助10
10秒前
10秒前
10秒前
思源的应助被正在采纳,获得10
11秒前
云岚发布了新的文献求助10
11秒前
12秒前
雪山大地发布了新的文献求助10
12秒前
Ternura发布了新的文献求助10
12秒前
桐桐的应助被孤独的冷安采纳,获得10
13秒前
13秒前
秽鸢鸠梦发布了新的文献求助10
14秒前
yyyyyy发布了新的文献求助10
15秒前
自由初蝶的应助被结实的翠芙采纳,获得30
15秒前
小明同学发布了新的文献求助10
15秒前
科研通AI6.4的应助被jerry采纳,获得10
16秒前
16秒前
李爱国的应助被拖鞋采纳,获得10
16秒前
16秒前
健壮璎发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163922
求助须知:如何正确求助?哪些是违规求助? 9557995
关于积分的说明 21743022
捐赠科研通 7754548
什么是DOI,文献DOI怎么找? 3428401
关于科研通互助平台的介绍 2553053
邀请新用户注册赠送积分活动 2473008